Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Increased to $179.00 by Analysts at Royal Bank of Canada

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price upped by Royal Bank of Canada from $175.00 to $179.00 in a report released on Wednesday morning, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the specialty pharmaceutical company’s stock.

A number of other equities research analysts have also issued reports on the stock. Robert W. Baird decreased their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a research note on Thursday, August 1st. Needham & Company LLC reissued a “buy” rating and set a $205.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, September 10th. Cantor Fitzgerald reissued an “overweight” rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. HC Wainwright restated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Finally, UBS Group cut their price target on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a report on Tuesday, July 2nd. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $173.43.

Jazz Pharmaceuticals Trading Down 1.7 %

Jazz Pharmaceuticals stock opened at $111.13 on Wednesday. The company has a 50 day moving average price of $111.05 and a 200 day moving average price of $109.66. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $134.48. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37. The firm has a market capitalization of $7.01 billion, a price-to-earnings ratio of 22.91, a P/E/G ratio of 1.34 and a beta of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 EPS for the quarter, topping analysts’ consensus estimates of $3.80 by $0.87. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. Research analysts forecast that Jazz Pharmaceuticals will post 16.03 EPS for the current year.

Insider Buying and Selling

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares in the company, valued at $1,573,707.30. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Kovack Advisors Inc. increased its holdings in shares of Jazz Pharmaceuticals by 88.8% during the 1st quarter. Kovack Advisors Inc. now owns 56,599 shares of the specialty pharmaceutical company’s stock worth $6,816,000 after purchasing an additional 26,628 shares during the period. John G Ullman & Associates Inc. bought a new position in shares of Jazz Pharmaceuticals during the 1st quarter worth about $3,631,000. Swedbank AB bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth about $106,936,000. Vanguard Group Inc. increased its holdings in shares of Jazz Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock worth $776,551,000 after purchasing an additional 84,941 shares during the period. Finally, LSV Asset Management increased its holdings in shares of Jazz Pharmaceuticals by 1.6% during the 1st quarter. LSV Asset Management now owns 2,380,858 shares of the specialty pharmaceutical company’s stock worth $286,703,000 after purchasing an additional 37,631 shares during the period. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.